Tumor necrosis factor-alpha antagonist therapy-induced psoriasis in Turkey: Analysis of 514 patients

Modern Rheumatology

Volumn 22, Issue 5, 2012, Pages 738-742

  Dalkilic, Ediz ^a,b   Baskan, Emel Bulbul ^a   Alkis, Nihan ^a   Gullulu, Mustafa ^a   Yavuz, Mahmut ^a   Dilek, Kamil ^a   Ersoy, Alpaslan ^a   Yurtkuran, Mustafa ^a  

^a ULUDAG UNIVERSITY   (Turkey)

^b Bademli mah E itim cad   (Turkey)

Author keywords

Drug induced psoriasis; Rheumatoid arthritis; Spondyloarthropathy; Tumor necrosis factor antagonist

Indexed keywords

ADALIMUMAB; CYCLOSPORIN A; ETANERCEPT; HYDROXYCHLOROQUINE; INFLIXIMAB; LEFLUNOMIDE; METHOTREXATE; RHEUMATOID FACTOR; RITUXIMAB; SALAZOSULFAPYRIDINE; TUMOR NECROSIS FACTOR ALPHA INHIBITOR;

ANKYLOSING SPONDYLITIS; ARTICLE; CLINICAL ARTICLE; CORTICOSTEROID THERAPY; DESQUAMATION; DIABETES MELLITUS; DISEASE DURATION; DISEASE SEVERITY; DRUG WITHDRAWAL; ERYTHEMA; FEMALE; HUMAN; INFECTION RISK; MALE; PRIORITY JOURNAL; PSORIASIS; PUSTULAR PSORIASIS; REMISSION; RHEUMATOID ARTHRITIS; SKIN BIOPSY; SKIN DEFECT; SYSTEMIC THERAPY;

ADULT; ANTIBODIES, MONOCLONAL; ANTIRHEUMATIC AGENTS; ARTHRITIS, RHEUMATOID; DRUG SUBSTITUTION; FEMALE; HUMANS; MALE; MIDDLE AGED; PSORIASIS; SKIN; SPONDYLITIS, ANKYLOSING; TUMOR NECROSIS FACTOR-ALPHA;

EID: 84870380766     PISSN: 14397595     EISSN: 14397609     Source Type: Journal    
DOI: 10.1007/s10165-011-0590-9     Document Type: Article

References (21)

1. Rychly DJ, DiPiro JT. Infections associated with tumor necrosis factor-Alpha antagonists. Pharmacotherapy. 2005;25:1181-92.
2. Keane J, Gershon S, Wise RP, Mirabile-Levens E, Kasznica J, Schwieterman WD, et al. Tuberculosis associated with infliximab, a tumor necrosis alpha-neutralizing agent. N Engl J Med. 2001;345:1098-104.
3. Gomez-Reino JJ, Carmona L, Angel Descalzo M, Biobadaser Group. Risk of tuberculosis in patients treated with tumor necrosis factor antagonists due to incomplete prevention of reactivation of latent infection. Arthritis Rheum. 2007;57:756-61.
4. Fernandez-Torres R, Paradela S, Valbuena L, Fonseca E. Infliximab induced lichen planopilaris. Ann Pharmacother. 2010;44: 1501-3.
5. Dhaille F, Viseux V, Caudron A, Dadban A, Tribout C, Bournier P, et al. Cutaneous sarcoidosis occurring during anti-TNF-Alpha treatment: report of two cases. Dermatology. 2010;220:234-7.
6. Lourari S, Prey S, Livideanu C, Jarnard B, Lamant L, Cantagrel A, et al. Cutaneous T-cell lymphoma following treatment of rheumatoid arthritis with tumor necrosis factor-Alpha blocking agents: two cases. J Eur Acad Dermatol Venereol. 2009;23:967-8.
7. Justice EA, Khan SY, Logan S, Jobanputra P. Disseminated cutaneous Herpes Simplex Virus-1 in a woman with rheumatoid arthritis receiving infliximab: a case report. J Med Case Rep. 2008;26:282.
8. Kain T, MacGregor D, Buchanan RR, de Jager JP, Schachna L. Erythema multiforme with tumor necrosis factor inhibitors: a class affect? Ann Rheum Dis. 2008;67:899-900.
9. Sari I, Akar S, Birlik M, Sis B, Onen F, Akkoc N. Antitumor necrosis factor-Alpha induced psoriasis. J Rheumatol. 2006;33: 1411-4.
10. Park BC, Lim HJ, Kim BS, Lee WJ, Kim do W, Lee SJ. Repeated paradoxical aggravation of preexisting psoriasis during infliximab treatment for Crohn's disease. Ann Dermatol. 2009;21:60-2.
11. Rallis E, Korfitis C, Stauropovlou E, Papaconstantis M. Onset of palmoplantar pustular psoriasis while on adalimumab for psoriatic arthritis: a class effect of TNF-Alpha antagonists or simply an anti-psoriatic treatment adverse reaction? J Dermatol Treat. 2010;21:3-5.
12. Collamer AN, Battafarano DF. Psoriatic skin lesions induced by tumor necrosis factor antagonist therapy: clinical features and possible immunopathogenesis. Semin Arthritis Rheum. 2010;40: 233-40.
13. Wollina U, Hansel G, Koch A, Schönlebe J, Kö stler E, Haroske G. Tumor necrosis factor-Alpha inhibitor-induced psoriasis or psoriasiform exanthemata: first 120 cases from the literature including a series of 6 new patients. Am J Clin Dermatol. 2008;9:1-14.
14. Harrison MJ, Dixon WG, Watson KD, King Y, Groves R, Hyrich KL, et al. Rates of new-onset psoriasis in patients with rheumatoid arthritis receiving anti-Tumor necrosis factor-Alpha therapy: results from the British Society for Rheumatology Biologics Register. Ann Rheum Dis. 2009;68:209-15.
15. Ko JM, Gottlieb AB, Kerbleski JF. Induction and exacerbation of psoriasis with TNF-blockade therapy: a review and analysis of 127 cases. J Dermatol Treat. 2009;20:100-8.
16. Cohen JD, Bournerias I, Buffard V, Paufler A, Chevalier X, Bagot M, et al. Psoriasis induced by tumor necrosis factor-Alpha antagonist therapy: a case series. J Rheumatol. 2007;34:380-5.
17. Fouache D, Goeb V, Guillemant NM, Avenel G, Deschryver HB, Meurice MK, et al. Paradoxical adverse events of anti-Tumor necrosis factor therapy for spondyloarthropathies: a retrospective study. Rheumatology. 2009;48:761-4.
18. Nestle FD, Conrad C, Conrad C, Tun Kyi A, Homey B, Gombert M, Boyman O, et al. Plasmacytoid predendritic cells initiate psoriasis through interferon-Alpha production. J Exp Med. 2005;202:135-43.
19. Cuchacovich R, Espinoza CG, Virk Z, Espinoza LR. Biologic therapy (TNF-[alpha] antagonists)-induced psoriasis: a cytokine imbalance between TNF-[alpha] and IFN [alpha]. J Clin Rheumatol. 2008;14:353-6.
20. Collamer AN, Guerrero KT, Henning JS, Battafarano DF. Psoriatic skin lesions induced by tumor necrosis factor antagonist therapy: a literature review and potential mechanisms of action. Arthritis Rheum. 2008;59:996-1001.
21. Wendling D, Balblane JC, Briancon D, Brausse A, Lohse A, Deprez P, et al. Onset or exacerbation of cutaneous psoriasis during TNF-Alpha antagonist therapy. Joint Bone Spine. 2008;75: 315-8.